Tat-K13 peptide inhibits PTEN nuclear translocation, attenuating autophagy and enhancing neurological recovery post-HIE.

Neuronal death triggered by hypoxia-ischemia (HI) is a major cause of neonatal mortality and long-term neurological deficits. Excessive autophagy plays a pathogenic role in neonatal hypoxic-ischemic encephalopathy (HIE). The phosphatase and tensin homolog deleted on chromosome TEN (PTEN) is a key regulator, and its nuclear translocation is a critical event. Targeting this specific pathway offers a potential therapeutic strategy to mitigate HIE-related damage.

The study investigated the effects of peptide Tat-K13 on neonatal hypoxic-ischemic brain damage. Researchers employed Western blotting, immunofluorescence, and enzyme-linked immunosorbent assays to assess expression levels of pyroptosis-, autophagy-, lysosomal membrane permeabilization (LMP)-, and MAPK signalling-related proteins. Specific details regarding the model (e.g., species), sample size, dose, route, frequency, or duration of Tat-K13 administration were not provided in the abstract.

Inhibition of PTEN nuclear translocation by peptide Tat-K13 was observed as a primary mechanism. This inhibition led to the attenuation of p-JUN-SESN2-AMPK-dependent autophagy, a pathway implicated in cellular damage. The overarching outcome reported was an enhancement of neurological recovery following neonatal hypoxic-ischemic brain damage. This suggests a direct link between Tat-K13's action on PTEN, reduced autophagy, and improved functional outcomes. > Tat-K13 effectively inhibits PTEN nuclear translocation, reducing autophagy and improving neurological outcomes. No specific quantitative data, such as percentages, fold-changes, or p-values, were reported in the abstract regarding the extent of autophagy attenuation or neurological recovery.